Sandoz reports that it has completed, ahead of schedule, the acquisition of US biosimilar Cimerli (ranibizumab-eqrn) from Coherus BioSciences, in accordance with the January agreement for a purchase price of $170 million.

With the addition of Cimerli to our existing ophthalmology franchise, we can offer even more treatment options to U.S. patients suffering from vision impairment and loss," comments Keren Haruvi, President of Sandoz North America.

A biosimilar to Lucentis, Cimerli is indicated for the treatment of certain retinal diseases that, if left untreated, can lead to vision loss, which ranks among the top 10 causes of disability in the U.S.

Copyright (c) 2024 CercleFinance.com. All rights reserved.